Should GA therapy start monthly—or is less-than-monthly treatment enough? In episode 3 of this New Retina Radio miniseries, moderator John Kitchens, MD joins David Eichenbaum, MD; Margaret Chang, MD, MS; and Ferhina Ali, MD, MPH, to share best practices in real-world GA care. The panel debates dosing strategy in light of long-term data, compares safety/efficacy considerations for pegcetacoplan vs avacincaptad pegol (including first-injection inflammation risk), and offers tips for initiating therapy in monocular patients. They also unpack evidence around AREDS vitamins and early experiences with photobiomodulation.
This content is editorially independent, supported by Astellas Pharma.